These effects of tocilizumab may be independent of its therapeutic effect in RA patients and it has been doubted whether classical surrogate markers (for example, ESR, CRP) are suitable for measuring therapy efficacy in tocilizumab-treated RA patients [12]. Here, CRP is linked to rheumatoid arthritis.